More evidence that aspirin may not be necessary in long-term antiplatelet therapy after ACS

Media formats available:

Ready to Claim Your Credits?

You have attempts to pass this post-test. Take your time and review carefully before submitting.

Good luck!

A rise in adverse clinical events with NOAC-regime after TAVR resulted in termination of trial
A rise in adverse clinical events with NOAC-regime after TAVR resulted in termination of trial
AHA 2019
A rise in adverse clinical events with NOAC-regime after TAVR resulted in termination of trial
- Prof. Freek Verheugt, MD
Single dose colchicine prior to PCI reduces rise in inflammation, but does not give reduction in MI and MACE
Single dose colchicine prior to PCI reduces rise in inflammation, but does not give reduction in MI and MACE
AHA 2019
Single dose colchicine prior to PCI reduces rise in inflammation, but does not give reduction in MI and MACE
ARNI seems to give CV benefit not only in HFrEF, but up to EF of about 60%
ARNI seems to give CV benefit not only in HFrEF, but up to EF of about 60%
AHA 2019
ARNI seems to give CV benefit not only in HFrEF, but up to EF of about 60%
- Scott Solomon, MD
Fish oil treatment reduces several plaque parameters after 9 months
Fish oil treatment reduces several plaque parameters after 9 months
AHA 2019
Fish oil treatment reduces several plaque parameters after 9 months
- Prof. Lawrence Leiter, MD